Australian Biotech

This week, we mark a significant anniversary, discuss the risks of missing the opportunity that artificial intelligence offers to speed access to healthcare, and explore why some might be reluctant to embrace it. The wonderful irony of the phrase of the week.

Australians living with a rare genetic form of motor neurone disease will gain access to an innovative treatment from 1 October, with the reimbursement of Biogen's QALSODY (tofersen).

In a further expansion of pharmacists' role, the government announced a new care trial that will let participating pharmacists treat ear infections, provide wound care, and help manage chronic conditions including hypertension and chronic obstructive pulmonary disease.

AI in healthcare is being decided right now. Are you leading or following? On 9 November in Sydney leaders in pharma, biotech and health policy in Australia will be in one room, working through...

The United States is marking an important legislative milestone that unlocked university-led innovation, while some in Australia still maintain that the government deserves pricing consideration for commercialised products that may have received some funding support in the distant past.

After twelve years steering the Private Cancer Physicians of Australia through some of the most consequential fights in Australian cancer policy, Christopher Steer has handed the presidency to Cameron McLaren.

Two accounts of how the Pharmaceutical Benefits Advisory Committee weighs patient and clinician voices arrived within weeks of each other, and they do not sit comfortably together.

A Sydney company has become the first in Australia to earn a manufacturing licence for viral vectors, a milestone it says strengthens the nation's capacity to make advanced gene and cell therapies at home rather than relying on overseas suppliers.

Why does a submission drafted with AI assistance, assessed by an evaluator using AI assistance, and discussed by committee members who each turned to different tools to prepare, still have to land on the same calendar date it always did?

We live in a wealthy country where this situation has been allowed to persist. Responsibility is not shared equally. Those with the authority to design, operate and change the system carry a greater obligation than the rest of us.

Australia's national powerchair football team, the Poweroos, is heading to Buenos Aires this October with Biogen in its corner. 

Among the patient advocates, parliamentarians and pharmaceutical executives who gathered in Canberra on Tuesday for the fifth annual Patient and Parliament Summit, organised by Bristol Myers Squibb, no politician delivered the sharpest verdict on the state of Australia's medicines system. It was a journalist.